News | January 14, 2008

Ablation System for AF Earns 82 Percent Success Rate

January 15, 2008 - Surgeons and electrophysiologists who used AtriCure's endoscopic bipolar ablation system to treat atrial fibrillation (AF) said the procedure was successful in 82 percent of patients that presented with paroxysmal AF and 56 percent of patients that presented with persistent and long-standing persistent AF in a report published in the Journal of Interventional Cardiac Electrophysiology.

The authors of the study, James R. Edgerton, M.D., and Michael B. Mack,M.D., from the Cardiopulmonary Research Science and Technology Institute of Dallas, Texas in collaboration with Warren M. Jackman, M.D., an electrophysiologist from the University of Oklahoma, reported on results from 83 patients who underwent a video-assisted, minimally invasive ablation procedure for the treatment of AF using AtriCure's Isolator endoscopic bipolar ablation system. The procedure included electrical isolation of the pulmonary veins, confirmed by electrophysiology mapping techniques, targeted autonomic denervation of the left atrium and the removal of the left atrial appendage in selected patients. The study population consisted of patients with left atrial enlargement as the authors reported a mean left atrial size of 5.2cm. Left atrial enlargement is known to be one of the primary predictors of ablation failures. Additionally, 25 percent of the patients had at least one previous catheter ablation failure.

Of the 83 patients, 57 completed long-term monitoring at 6 months. Treatment success was defined as no episodes of AF greater than 15 seconds in duration. The minimally invasive procedure was successful in 32 of 39 (82 percent) of patients that presented with paroxysmal AF and 10 of 18 (56 percent) of patients that presented with persistent and long-standing persistent AF.

Dr. Edgerton commented, "The results from this study are very encouraging and support the safety and effectiveness of this procedure and products in a selected group of AF patients. We remain enthusiastic concerning the continued development and investigation of these minimally invasive products and techniques. In particular, we have developed an expanded ablation procedure and we are encouraged by the potential for the expanded ablation procedure to improve clinical outcomes in the more difficult to treat persistent and permanent AF patients."

For more information: www.atricure.com

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init